Enara Bio’s mission is to shine a light on unconventional targets and develop the next generation of cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from altered cellular processes in cancer cells.

Biotechnology

Enara Bio

Anonymous

Adam Taylor

Jonathan Porter

Sophie Papa

Soreya Senior

Duncan Howie

Andrew Fadden

Luke Williams

Ray Duffy

Simon Jarvis

Jo Senra

Ron Wolchinsky

Bethany Turner

Nicola Ternette

Fabio Marino

Charlotte Howard

Joseph Dukes

Jonathon Dines

David Watson

The Research and Development team at Enara Bio focuses on discovering and characterizing novel immunotherapy targets for cancer treatment. This multidisciplinary team leverages their expertise in immunopeptidomics, molecular immunology, cell process development, and bioinformatics to explore unconventional targets such as MR1-presented ligands and Dark Antigens™. Their work involves identifying and validating these novel targets, advancing preclinical research, and ultimately contributing to the development of next-generation cancer immunotherapies.

Research and Development

Directors

Leadership Team

Research and Development

About

Team members

Other teams at Enara Bio

Directors

Leadership Team